by Erin | Jul 17, 2026 | Blog
When Colorado defended its proposed price cap on Enbrel in federal court, it didn’t deny that someone would take a financial hit. It simply argued the hit didn’t have to land on the plaintiff in the case, the manufacturer. On July 1, 2026, a federal judge...
by Erin | Feb 18, 2026 | Blog
Polling by the Value of Care Coalition shows that when it comes to decisions about their health care, patients trust doctors (82%) — not government boards and panels (1%). If an option were included for “government officials in foreign countries,” it’s not hard to...
by Erin | Oct 22, 2025 | Blog
As states authorize and implement Prescription Drug Affordability Boards, health care stakeholders have raised concerns about both their decision-making processes and the potential negative consequences of those decisions. PDABs are inherently state-based...
by Erin | Sep 10, 2025 | Blog
Everyone knows you can’t compare apples and oranges. Yet that’s exactly what prescription drug affordability boards do when they make decisions about value. Now, a new video from the Value of Care Coalition outlines how this one-size-fits-all approach ignores clinical...
by Erin | Jul 28, 2025 | Blog
Specialty doctors are concerned about the harmful impacts of prescription drug affordability boards, a white paper commissioned by the Value of Care Coalition recently found. The survey asked endocrinologists, rheumatologists and HIV specialists for their opinions on...
by Erin | Jul 16, 2025 | Blog
While some states continue to struggle with the operations of Prescription Drug Affordability Boards (PDABs), others are saying “no” to upper payment limits altogether. This year, the governors of Virginia and Nevada vetoed legislation that would have either...
